
æ·±ãæžå¿µïŒ ä»å¹Žã®ã€ã³ãã«ãšã³ã¶äºé²æ¥çš®ã§ã€ã³ãã«ãšã³ã¶ã®ãªã¹ã¯ã27ïŒ äžæ
å èšäºã¯ãã¡ããã/Click here to read the original article.
2024ïœ2025幎ã®ã€ã³ãã«ãšã³ã¶ã·ãŒãºã³åãã«è£œé ãããã¯ã¯ãã³ãæ¥çš®ãã人ã¯ãæ¥çš®ããªãã£ãäººã«æ¯ã¹ãŠã€ã³ãã«ãšã³ã¶ã«ããããªã¹ã¯ã27ïŒ é«ãã£ããšããæ°ããªãã¬ããªã³ãç ç©¶ãçºè¡šããããä»ã·ãŒãºã³ã®ã¯ã¯ãã³ã¯ã€ã³ãã«ãšã³ã¶äºé²ã«å¹æçã§ã¯ãªãã£ãå¯èœæ§ãããããšç€ºåããŠããã
2024ïœ2025幎ã·ãŒãºã³åãã«è£œé ãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ãã人ã¯ãæ¥çš®ããŠããªãäººã«æ¯ã¹ãŠã€ã³ãã«ãšã³ã¶ã«ããããªã¹ã¯ã27ïŒ é«ãã£ãããšããæ°ããªãã¬ããªã³ãç ç©¶ã«ãã£ãŠç€ºãããããã®çµæã¯ããä»ã·ãŒãºã³ã®ã€ã³ãã«ãšã³ã¶äºé²ã«ãããŠãã¯ã¯ãã³ã¯å¹æçã§ãªãã£ãå¯èœæ§ããããããšã瀺åããŠããã
ãã®ç ç©¶ã¯ããªãã€ãªå·ã«ããéå¶å©ã®åŠè¡å»çã»ã³ã¿ãŒãã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ãã®è·å¡53,402人ã察象ã«å®æœããããã®ã§ãã¯ã¯ãã³ã®â广âã¯ãã€ãã¹26.9%ãšããçµæã ã£ãã
ãã®ç ç©¶ã¯ãå é±MedRxivïŒã¡ãã¢ãŒã«ã€ãïŒãšãããã¬ããªã³ããµãŒããŒã«æ²èŒããããè«æã«ã¯æ¬¡ã®ããã«æžãããŠããïŒ
ãåœåã¯ã¯ã¯ãã³æ¥çš®è ãšéæ¥çš®è ã®éã§ã€ã³ãã«ãšã³ã¶ã®çޝç©çºççã«å€§ããªéãã¯èŠãããªãã£ãããç ç©¶æéãé²ãã«ã€ããææã®çޝç©çºççã¯ã¯ã¯ãã³æ¥çš®è ã®æ¹ãéæ¥çš®è ãããæ¥éã«å¢å ããŠãã£ããã
ãã®çµæã«ã€ããŠãå»çç³»ãã¥ãŒã¹ãµã€ããTrialSite Newsãã¯ãä¿è·ã©ããã害ããããããŠããå¯èœæ§ããããå ¬è¡è¡çåœå±ã«ããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®äž»åŒµãšççŸãããæ¥µããŠææ ®ãã¹ãçµæã ããšè¿°ã¹ãŠããã
ç«åŠè ã®ãã³ã©ã¹ã»ãã«ã·ã£ãŒæ°ã¯ãããã®ã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã®ç ç©¶ã¯ãæ¯å¹Žã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãå®å šã«å€±æããŠããããšãæããã«ããŠãããã¢ã¡ãªã«åœæ°ã¯ãæå®³ç©è³ªãå«ãã æ³šå°è£œåã«ãã£ãŠå¥åº·ãæãªãããšã«ããããããŠããããšè¿°ã¹ãã
ãŸããã¯ã¬ã€ãã³ã»Jã»ãã€ã«ãŒå»åž«ã¯ãããã®ç ç©¶çµæã¯ãã¯ã¯ãã³ãæããã«æå®³ã§ãã£ãããšã匷ã瀺ããŠããããšèªã£ãããä»å¹Žã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã倧倱æã ã£ãããšã瀺ãã ãã§ãªããåŒåžåšç³»ãŠã€ã«ã¹ã«å¯Ÿããå£ç¯æ§ã®å€§èŠæš¡ã¯ã¯ãã³æ¥çš®ãšããåãçµã¿å šäœã«å¯ŸããŠæ·±å»ãªçåãæããããŠããããšææããŠããã
å ç§å»ã®ã¡ãªã«ã»ãã¹å»åž«ã¯ããã®çµæã«é©ãã¯ãªããšè¿°ã¹ãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã¯ã䜿çšåã«æå¹æ§ã®è©ŠéšããããŠããªãããšãããéå»ã«æ¿èªãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®ã©ã€ã»ã³ã¹ãåºã«âç¶ç¶çã«â䜿çšãããŠãããå®å šæ§è©Šéšãããåºæ¬çãªãã®ã«ãšã©ãŸã£ãŠããããã®ãããâè² ã®æå¹æ§âãèµ·ããããšãããåŸãããšèª¬æããã
ãè¿å¹Žæã圱é¿åã®ããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ç ç©¶ã®ã²ãšã€ã
ãã®ç ç©¶ã¯ãŸã æ»èªãåããŠããªããã®ã®ãç§åŠè ãå»çå°éå®¶ã®éã§ã¯æ¹æ³è«çã«ä¿¡é Œã§ãããšè©äŸ¡ãããŠãããã¯ã¬ã€ãã³ã»ãã€ã«ãŒå»åž«ã¯ãããã¯å€§èŠæš¡ã§ãæããã«è¯ãèšèšãããç ç©¶ã ã£ããçµæã¯çå£ã«åãæ¢ããã¹ãã ããšè¿°ã¹ãã
ã¡ãªã«ã»ãã¹å»åž«ããç ç©¶è ãã¡ã¯ãåªããããŒã¿ã»ããããçšããåå è ãã¯ã¯ãã³ãæ¥çš®ããæ¥ä»ãããã®åŸã€ã³ãã«ãšã³ã¶éœæ§ãšå€å®ãããæ¥ä»ãå«ãå®å šãªã¿ã€ã ã©ã€ã³ãèšé²ãããŠãããšææããã
TrialSite News ã¯ããä»åã®ç 究察象ã¯äžé©åãªéå£ã§ã¯ãªãã£ãããšãããå¹³å幎霢42æ³ã®æ¯èŒçè¥ãå±€ã§ãå¥åº·ç¶æ ãè¯å¥œãè·æ¥äžã®ã«ãŒã«é å®ãé«ãã£ããâŠãã®çµæã¯æ»èªãããã¹ãã ããšå ±ããŠããã
ç ç©¶è ã§èè ã®ãžã§ãŒã ãºã»ã©ã€ãªã³ãºïŒã¯ã€ã©ãŒå士ã¯ãèªèº«ã®Substackã«ãŠããã®ç ç©¶ã¯ãè¿å¹Žçºè¡šãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ç ç©¶ã®äžã§ãæãéèŠãªãã®ã®ã²ãšã€ã ããšè¿°ã¹ãããã®çç±ãšããŠãå¯Ÿè±¡è æ°ã®å€ããå®ç掻ã«å³ããç ç©¶ãã¶ã€ã³ããªã¹ã¯ããŒã¹ã®è©äŸ¡ææšãå ç¢ãªçµ±èšææ³ããããŠè£œè¬æ¥çããã®è³éæäŸããªãã£ãç¹ãæããŠããã
ã©ã€ãªã³ãºïŒã¯ã€ã©ãŒå士ã¯ãããã®ãããªèŠæš¡ãšæå¿«ãããããŠç¬ç«æ§ãæã€ç ç©¶ã§ãåœå®¶ã®ã¯ã¯ãã³æ¿çãšçã£åãã察ç«ããçµæãåºãããšã¯éåžžã«çããããšãèšããŠããã
ãã€ã«ãŒå»åž«ãåæãããã¯ã¯ãã³ãé°æ§ã®å¹æïŒïŒæ¥çš®ã«ãã£ãŠç æ°ã«ããããªã¹ã¯ãé«ãŸãïŒã瀺ãããšããããšã¯ãäœããã®æå³ããªãå ç«é害ãåŒãèµ·ãããå¯èœæ§ã瀺åããŠãããããã¯ãã¯ã¯ãã³éçºè ãã¡ãèªåãã¡ã®è£œåãå ç«ã·ã¹ãã ã«ã©ã®ããã«äœçšããŠããããååã«çè§£ããŠããªãããšãæå³ããããšè¿°ã¹ãã
ããã«åœŒã¯ãã補è¬äŒæ¥ããã€ã³ãã«ãšã³ã¶ã«ãããå¯èœæ§ããé«ããŠããŸããããªã¯ã¯ãã³ã®è£œé ãé¿ããããªãã®ã§ããã°ãæ¯å¹Žå¹æçãªã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãäœãããšããåªåãã®ãã®ãè¶çªã§ããããã«æããããšãèªã£ãã
ãªããç ç©¶è«æã®äžã§ããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®å¹æã¯ããã®å¹Žããšã®ããŸããŸãªèŠå ã«å·Šå³ããããããçŸåšã®è£œé ããã»ã¹ã§ã¯ãæ¯å¹Žé«ãæå¹æ§ãæåŸ ããã®ã¯çŸå®çã§ãªãã®ãããããªãããšèšãããŠããã
ç ç©¶çµæã¯ãåäŸããªãããã§ã¯ãªãã
ãã®ç ç©¶ã«ãããšãã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã®è·å¡ã¯ãæ¯å¹Žã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ããããå»ççãŸãã¯å®æçãªçç±ã§å é€ãåãããã®ãããããéžã¶ããšã®ããšã§ãã
Childrenâs Health Defenseã®ã·ãã¢ãªãµãŒããµã€ãšã³ãã£ã¹ãã§ããã«ãŒã«ã»ãžã£ããããŠã¹ããŒå士ã¯ããããã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã宿çå é€ãèªããŠããªãã£ããªãããã®ç ç©¶ã¯äžå¯èœã ã£ãã ããããšè¿°ã¹ãŸããããå»ççãŸãã¯å®æçã«å é€ããã人ã ããæ¥çš®ã矩åã¥ãããã人ã ãããã€ã³ãã«ãšã³ã¶ãæ£è ã«åºãããªã¹ã¯ãèããäœãã£ããšããã®ã¯ãå šããã£ãŠäžåçã ããšåŒ·èª¿ããŸããã
ã©ã€ãªã³ãºïŒã¯ã€ã©ãŒå士ã¯ãç ç©¶çµæããåäŸã®ãªããã®ã§ã¯ãªãããšææããŸããã圌ã¯2012幎ã«ãClinical Infectious Diseasesãèªã«çºè¡šãããæ»èªæžã¿ã®ç ç©¶ãåŒçšãããã®ç ç©¶ã§ã¯ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ããåäŸãã¡ãéã€ã³ãã«ãšã³ã¶ã®åŒåžåšãŠã€ã«ã¹ææçã«ããããªã¹ã¯ãææã«é«ãããšã瀺ãããŠãããšè¿°ã¹ãŸããã
ãŸããæšå¹ŽãScientific Reportsãèªã«çºè¡šãããæ»èªæžã¿ã®ç ç©¶ã§ã¯ã19çš®é¡ã®ã¯ã¯ãã³ã調æ»ããããã®ãã¡17çš®é¡ã®ã¯ã¯ãã³ïŒã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãå«ãïŒãã®ã©ã³ã»ãã¬ãŒçå矀ãšãããæ«æ¢¢ç¥çµç³»ãæ»æããçšãªç æ°ã®çºçãšé¢é£ããŠããããšãå ±åãããŠããŸãã
ã»ãšãã©ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«ã¯ç¥çµçºéé害ã«é¢é£ããæåãå«ãŸããŠãã
ãã®ç ç©¶ã«ãããšãä»ã·ãŒãºã³ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã广çã§ãªãã£ãçç±ã®ã²ãšã€ã¯æ ªã®äžäžèŽã§ãããã¯ã¯ãã³ãä¿è·ããæ ªãšå®éã«ææãåŒãèµ·ãããæ ªãç°ãªã£ãŠããããšãæããããŠããŸãã
ãã¯ã¯ãã³æ ªãšåŸªç°ããæææ ªãšã®éã«ä¹é¢ããã幎ã«ã¯ãã¯ã¯ãã³ã®å¹æãäœãããšãäºæ³ãããããšç ç©¶ã¯ææããŠããŸãã
ã©ã€ãªã³ãºïŒã¯ã€ã©ãŒå士ã¯ããæãå¯èœæ§ã®é«ã説æã¯ãã¯ã¯ãã³ã«ããå ç«èª¿ç¯ãé¢äžããŠããããšã§ãããã¯ã¯ãã³æ¥çš®ã«ããäºåã®æé²ããç¹ã«æ ªã®äžäžèŽãããå Žåã«ã埪ç°ããæ ªã«å¯Ÿããå ç«ç³»ã®åå¿èœåãäœäžãããå¯èœæ§ãããããšè¿°ã¹ãŠããŸãã
ãŸããã©ã€ãªã³ãºïŒã¯ã€ã©ãŒå士ã¯ãã»ãšãã©ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«ã¯ãã¡ããµãŒã«ãå«ãŸããŠããããšã«ãèšåããŠããŸããããã¡ããµãŒã«ã¯ãããã€ãã®å€éæäžçšã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«äœ¿çšãããŠããæ°ŽéããŒã¹ã®ä¿åæã§ãããç ç©¶ã«ãããšã98.7ïŒ ã®åå è ããã¡ããµãŒã«ãå«ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ããŠããŸããã
ãã¡ããµãŒã«ã¯æ°ŽéããŒã¹ã®ä¿åæã§ãäžéšã®ã¯ã¯ãã³ã«äœ¿çšãããŠããŸããããã«ããè³å ã§ç¡æ©æ°Žéãèç©ãããããšãé¢é£ä»ããããŠããŸãã2001幎ã®å»åŠç ç©¶æã®å ±åæžã§ã¯ããã¡ããµãŒã«ãžã®æé²ãšç¥çµçºéé害ãšã®éã«ãçç©åŠçã«åŠ¥åœãªãé¢é£æ§ãããããšã瀺åãããŠããŸãã
ãå€ãã®äžäŸ¡äžæŽ»åã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«ã¯ãã¡ããµãŒã«ãå«ãŸããŠãããæ¥çš®è ã®å ç«ç³»ã匱ããæœåšçãªåå ãšããŠèæ ®ãã¹ãã ããšãžã£ããããŠã¹ããŒã¯è¿°ã¹ãŸããã
ãã¡ã«ããºã ã¯ç°ãªããããããŸããããååã¯åãã§ãïŒã¯ã¯ãã³æ¥çš®ã¯ãç¹å®ã®ç¶æ³äžã§åºç¯ãªå ç«åå¿ãæãªãå¯èœæ§ãããããšã©ã€ãªã³ãºïŒã¯ã€ã©ãŒåå£«ã¯æžããŠããŸãã圌ã¯ãã®ç ç©¶ããäžè²«ããå©çãããããããããã£ãŠå®³ãåãŒãå¯èœæ§ã®ããæ®éçãªã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãã£ã³ããŒã³ã®è³¢æãã«çåãæããããããšè¿°ã¹ãŠããŸãã
CDCã®ããŒã¿ã«ãããšã2023-2024幎ã®å¯å·æããã³ã€ã³ãã«ãšã³ã¶ã·ãŒãºã³äžã«ã€ã³ãã«ãšã³ã¶ããã³COVID-19ã¯ã¯ãã³ãæ¥çš®ããå»çåŸäºè ã®æ°ãæžå°ããŠãããããã¯ç é¢ã¹ã¿ããããã®ä»ã®å»çåŸäºè ããããã®ã¯ã¯ãã³ã«å¯ŸããŠçå¿µãæ±ããŠããå¯èœæ§ã瀺åããŠããŸãã
ãå¢å€§ããç念ãšã¯ã¯ãã³ç²ãã®æä»£ã«ãããŠãå ¬è¡è¡çåœå±ã¯ãã®ãããªããŒã¿ã«åãåããªããã°ãªããªã â ãããç¡èŠããŠã¯ãããªãããšTrialSite Newsã¯å ±ããŠããŸãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®å¹Žæ¬¡æŠç¥ã¯ãç¹ã«æ ªã®äžäžèŽããã幎ã«ã¯ãçå£ã«åèããå¿ èŠããããããããŸãããã
ãã¯ã¯ãã³æ¥çš®ã矩ååãã岿 ¢ãã¯ããã®ç ç©¶ã«ãã£ãŠè¬èã«ãããã¹ãã§ãããšãžã£ããããŠã¹ããŒã¯è¿°ã¹ãŸããããããåœå ã®äžæµå»çæ©é¢ãåŸæ¥å¡ã®çŸ©åã«åºã¥ããŠæ£è ãå±éºã«ãããã®ã§ããã°ããã¹ãŠã®æ©é¢ã§ã®çŸ©ååã¯ãé¿ããã害ãåŒãèµ·ããå¯èœæ§ããããã